Valuation : Lupin Limited

Market Cap 984B 10.42B 8.99B 8.47B 7.71B 14.42B 14.53B 100B 38.9B 503B 39.12B 38.27B 1,653B P/E 2027 *
22.4x
P/E 2028 * 21.1x
Enterprise Value 945B 10B 8.63B 8.13B 7.41B 13.85B 13.95B 96.25B 37.36B 483B 37.57B 36.75B 1,587B EV / Sales 2027 *
3.12x
EV / Sales 2028 * 2.83x
Free-Float
52.98%
Yield 2027 *
0.59%
Yield 2028 * 0.59%
1 day+0.12%
1 week-1.03%
Current month-1.17%
1 month-10.83%
3 months-4.75%
6 months-6.46%
Current year+1.92%
1 week 2,136.1
Extreme 2136.1
2,209
1 month 2,136.1
Extreme 2136.1
2,447.95
Current year 2,072.95
Extreme 2072.95
2,530
1 year 1,881.9
Extreme 1881.9
2,530
3 years 1,091.8
Extreme 1091.8
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 01/09/2013
Director of Finance/CFO 61 13/08/2007
Compliance Officer - 01/09/2024
Director TitleAgeSince
Director/Board Member 52 08/10/2008
Director/Board Member 58 01/01/1997
Chairman 83 11/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%-1.03%+13.38%+96.89% 10.36B
+0.16%-2.04%+58.48%+108.73% 1,034B
+1.34%+1.99%+54.66%+71.38% 654B
+0.35%-0.77%+23.10%+78.55% 459B
+0.49%-5.19%+33.28%+35.53% 343B
+0.27%+3.26%+29.76%+47.50% 307B
+0.12%-2.11%+0.60%+12.03% 251B
+0.46%-0.04%+53.42%+73.29% 237B
+2.64%-1.08%-15.85%-53.97% 202B
-0.06%+1.15%+32.90%+99.29% 186B
Average +0.61%-2.71%+28.37%+56.92% 368.19B
Weighted average by Cap. +0.61%-3.31%+38.89%+68.13%

Financials

2027 *2028 *
Net sales 303B 3.21B 2.77B 2.61B 2.37B 4.44B 4.47B 30.85B 11.97B 155B 12.04B 11.78B 509B 322B 3.41B 2.94B 2.77B 2.52B 4.72B 4.75B 32.8B 12.73B 165B 12.8B 12.52B 541B
Net income 43.97B 465M 402M 378M 345M 644M 649M 4.48B 1.74B 22.48B 1.75B 1.71B 73.85B 46.7B 494M 426M 402M 366M 684M 689M 4.76B 1.85B 23.88B 1.86B 1.82B 78.43B
Net Debt -39.2B -415M -358M -337M -307M -574M -579M -3.99B -1.55B -20.04B -1.56B -1.52B -65.83B -74.03B -784M -676M -637M -580M -1.08B -1.09B -7.54B -2.93B -37.85B -2.94B -2.88B -124B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
02/09/26 2,152.60 +0.12% 237,462
01/09/26 ₹2,150.00 -1.29% 15,860
31/08/26 ₹2,178.00 +0.14% 25,043
28/08/26 ₹2,175.00 +0.48% 15,828
27/08/26 ₹2,164.60 -1.21% 48,999
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
2,152.60INR
Average target price
2,490.58INR
Spread / Average Target
+15.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock